RxDoctor Payments Data

Scott Freeman, MD

MOHS-Micrographic Surgery · Mobile, ALNPI 1851447460

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Organogenesis Inc. accounts for 65.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $984 and has fallen 58.0% since, to $413 in 2025.

$2,749in general payments, 2019–2025

Across 97 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$2K
  • AbbVie$373
  • Johnson & Johnson$122
  • Regeneron Healthcare Solutions, Inc.$93
  • Sanofi$67
  • UCB, Inc.$58
  • plus $241 from 9 others

What the payments were for

  • Food & beverage$2,749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,241,696
Medicare patients
849
Services billed
9,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorouracil57$5,364
Doxycycline Hyclate309$1,662
Gentamicin Sulfate17$781
Imiquimod21$694
Triamcinolone Acetonide40$662
Mupirocin59$516
Ketoconazole22$372
CiclopiroxCiclopirox Olamine14$260
Clindamycin Hcl29$197
Minocycline Hcl15$186
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$71
Ciprofloxacin Hcl11$39

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →